NCT05491044View on ClinicalTrials.gov

A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

August 28, 2024

Study Completion Date

August 30, 2024

Conditions
CLL/SLL
Interventions
DRUG

orelabrutinib

Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).

Trial Locations (2)

100044

NOT_YET_RECRUITING

Department of Hematology, Peking University People's Hospital, Beijing

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER